Malignant Solid Neoplasm — Trials

Malignant Solid Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

900 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 429
Recruiting: 209
Ph III recruiting: 10
Growth YoY: +2.3%
Industry share: 21%
Top sponsor: National Cancer Institute (NCI)
Termination share: 29.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (101)

clinicaltrialsPublishedShowing 51–100 of 144 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01709435	Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors	completed	Phase 1	41	National Cancer Institute (NCI)NIH	2	Dec 22, 2023	clinicaltrials
NCT02808650	Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors	completed	Phase 1	30	Children's Oncology GroupNETWORK	1	Dec 20, 2023	clinicaltrials